ClinicalTrials.gg
CompletedNCT07524738Updated Nov 12, 2026

Telemedicine XR-B for Individuals in Jail

A Phase 3 interventional study of Extended Release Buprenorphine in Opioid Use Disorder, sponsored by Friends Research Institute, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Friends Research Institute, Inc. · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Jun 2025, registered Apr 2026).
Updated Nov 12, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies testing sublocade in Opioid-Related Disorders — 2 open to participants now, 2 under way, none of them phase 3. Sublocade · Opioid-Related Disorders.

Enrollment
6th of 12
23 · median 21
Started
2025
with 1 other
Phase 3
3 of 12
none open now
Registered
12th of 12
by date
Lead sponsor
1 of 12
Friends Research Institute, Inc.

Among the 12 studies testing sublocade in Opioid-Related Disorders, this one is the 6th largest by enrollment, is one of 2 that started in 2025, is one of 3 in phase 3, and was the 12th registered.

Opioid-Related Disorders

1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

2 of the 12 studies testing sublocade in Opioid-Related Disorders are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About sublocade

Sublocade: first FDA approval 2017 (SUBLOCADE), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing sublocade in Opioid-Related Disorders, or all of them as a file.
02

Study summary

This study is an open label pilot study of 30 incarcerated men and women receiving sublingual buprenorphine (SL-B) in jail who will voluntarily switch to extended-release buprenorphine (BRIXADI) using telemedicine prior to release. Individuals will receive weekly XR-B and at least one monthly XR-B injection prior to release. Individuals will be linked to a community treatment provider where they will continue their treatment (buprenorphine) post-release. Participants will be assessed at 1,2-, and 3-months post release

Read the detailed description

This study is an open label pilot study of 30 incarcerated men and women receiving sublingual buprenorphine (SL-B) in jail who will voluntarily switch to extended-release buprenorphine (BRIXADI) using telemedicine prior to release. Individuals will receive weekly XR-B and at least one monthly XR-B injection prior to release. Individuals will be linked to a community treatment provider where they will continue their treatment (buprenorphine) post-release. Participants will be assessed at 1,2-, and 3-months post release.1) To determine the feasibility and willingness of individuals in jail to transition from telemedicine SL-B to XR-B and continue upon release in the community.

2) To examine (a) pharmacotherapy adherence pre release and community injections received), b) illicit opioid urine test results; (c) self-reported illicit opioid use; d) re-arrest and reincarceration; e) non-fatal and fatal overdose.

3) Explore barriers and facilitators to telemedicine XR-B implementation in jail: (1) telemedicine XR-B administration; (2) telemedicine staffing (both custody and medical); and (2) continuity of care after release to a community provider

03

Conditions studied

  • Opioid Use Disorder
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult male or female inmates at the participating jail who are eligible for release within 120 days (sentenced and/or pretrial [note: individuals who might be sentenced to state/federal prison will be excluded; individuals with detainers in another county will also be excluded]); Those individuals who are pre-trial and/or sentenced who are completing their sentence in the community (probation, parole, home detention, electronic monitoring, drug or other treatment court [or equivalent]) will be eligible to participate;
  2. History of opioid use disorder (meeting criteria of moderate or severe opioid use disorder at the time of incarceration; individuals not meeting the opioid-disorder criterion will be eligible if they were treated in an opioid agonist treatment program during the year before incarceration);
  3. Suitability for XR-B treatment as determined by medical evaluation;
  4. Willingness to enroll in XR-B treatment in jail and continue in the community;

Exclusion criteria

Exclusion Criteria:

  1. Active medical illness that may make participation hazardous (e.g., unstable diabetes, heart disease; moderate to severe renal impairment; adequately treated medical conditions are acceptable);
  2. Conditions or medications that may predispose to prolongation (personal or family history of long QT syndrome, hypokalemia, medications that prolong QTc interval, e.g., macrolide antibiotics, azole antifungal compounds, anti-arrythmics, antipsychotics and antidepressant);
  3. Untreated psychiatric disorder that may make participation hazardous (e.g., untreated psychosis, bipolar disorder with mania; adequately treated psychiatric disorders and appropriate psychotropic medications will be allowed);
  4. History of allergic reaction to buprenorphine;
  5. Suicidal ideation (within the past 3 months);
  6. Currently receiving non-buprenorphine MOUD in jail (methadone, naltrexone).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    XR-B

    extended-release buprenorphine

    Drug: Extended Release Buprenorphine

Interventions

06

What researchers measure

Primary outcomes

  1. medication adherence

    number of extended-release buprenorphine injections completed

    Time frame: three months post-release

Secondary outcomes

  1. illicit opioid use

    Illicit opioid use days using the Timeline Follow-Back (TLFB)

    Time frame: three months post-release

  2. Urine toxicology

    urine toxicology rapid test for illicit opioids

    Time frame: three months post-release

  3. overdose

    Opioid Overdose times non-fatal

    Time frame: three months post-release

07

Study locations

1 site
  • Allegany County Detention Center
    Cumberland, Maryland 21502, United States
08

References and documents

Individual participant data

Plan to share: No — Need additional information.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2025 to primary completion in Jun 2026, 12 months.

Of 31 phase 3 interventional studies under Opioid-Related Disorders, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's 12 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Jul 2026 → Jun 2026 and completion Sep 2026 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2026
First posted
Apr 13, 2026
StartActual
Jun 1, 2025
Primary completionActual
Jun 16, 2026was Jul 2026
CompletionActual
Aug 30, 2026was Sep 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 12, 2026
Primary completion
Jul 1, 2026→Jun 16, 2026 (actual)
Nov 12, 2026
Study completion
Sep 1, 2026→Aug 30, 2026 (actual)
Nov 12, 2026
Enrollment
30 (estimated)→23 (actual)
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Active, not recruiting→Completed
    Primary completion Jul 1, 2026→Jun 16, 2026 (now actual)
    Study completion Sep 1, 2026→Aug 30, 2026 (now actual)
    Enrollment 30 (estimated)→23 (actual)
    + 2 other changes: verification date and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07524738
Lead sponsor
Friends Research Institute, Inc.
Responsible party
Sponsor
First posted
Apr 13, 2026
Start date
Jun 1, 2025
Primary completion
Jun 16, 2026
Completion
Aug 30, 2026
Last update
Nov 12, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sublocade

Start the discussion